Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Bioasis Technologies Inc. > Prothena and Management's Reporting
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Oct 01, 2022 10:57am
129 Views
Post# 34999302

RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

RE:RE:RE:RE:RE:RE:Prothena and Management's ReportingMy objectivity?

Give us your take on Prothena.

Does xB3 work well enough to do business?

Why are the deals so small?

You can suggest whatever you want about my motives but it doesn't change the state that Bioasis is in.

I'll have a lot more to say before the AGM.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities